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A rectal carcinoma, including primary an adenosquamous and a squamous cell carcinoma (SCC), is a very rare disease, 
accounting for 0.025% to 0.20% of all large-bowel malignant tumors. Because SCCs have a higher mortality than adeno-
squamous carcinomas, determining whether the primary rectal cancer exhibits an adenomatous component or a squa-
mous component is important. While differentiating between these 2 components, especially in poorly differentiated rec-
tal cancer, is difficult, specific immunohistochemical stains enable accurate diagnoses. Here, we report the use of immu-
nohistochemical stains to distinguish between the adenomatous and the squamous components in 2 patients with low 
rectal cancer, a 58-year-old man and a 73-year-old woman, who were initially diagnosed using the histopathologic results 
for a poorly differentiated carcinoma. These data suggest that using these immunohistochemical stains will help to accu-
rately diagnose the type of rectal cancer, especially for poorly differentiated carcinomas, and will provide important infor-
mation to determine the proper treatment for the patient. 
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INTRODUCTION
Most rectal malignancies are adenocarcinomas, which are pri-
marily treated surgically, with selective use of neoadjuvant or ad-
juvant chemo-radiation for more locally advanced disease. Rectal 
primary adenosquamous carcinoma or squamous cell carcinoma 
(SCC) is very rare, with an incidence of 0.025% to 0.20% among 
all large bowel malignant tumors [1]. Most cases of rectal SCC are 
actually anal SCC with proximal extension into the rectum, which 
is different from primary SCC of the rectum. The estimated inci-
dence of primary rectal SCC is approximately 0.01%–0.025% of 
all colorectal neoplasms [2]. William et al. [3] established the fol-
lowing criteria to define SCC of rectal origin: (1) metastasis from 
other organs to the rectum must be ruled out; (2) there is an ab-
sence of anal involvement with SCC; and (3) an anal SCC-lined 
fistula with the rectum must be ruled out. Various treatment op-
tions are being used to manage rectal adenosquamous carcinoma 
or SCC, but there is still difficulty in determining appropriate 
treatments. While surgery is considered the gold-standard ther-
apy, the combination of radiotherapy and chemotherapy is an ef-
fective alternative therapy [4]. Thus, differentiating among adeno-
carcinoma, adenosquamous carcinoma, and SCC is a critical is-
sue. Using immunohistochemical stains may be an effective 
method to differentiate these pathologies. A study from Memorial 
Sloan Kettering Cancer Center showed that immunohistochemi-
cal stains are useful in distinguishing between adenosquamous 
carcinoma and SCC of the rectum, especially in poorly differenti-
ated cancer [5]. Therefore, we describe 2 cases of poorly differen-
tiated rectal cancer, in which various immunohistochemical stains 
reveal the final pathology containing either an adenomatous 
component or a squamous component. 
Received: August 3, 2015   •   Accepted: March 16, 2016
Correspondence to: Nam Kyu Kim, M.D.
Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, 
Seodaemun-gu, Seoul 03722, Korea
Tel: +82-2-2228-2105, Fax: +82-2-313-8289
E-mail: namkyuk@yuhs.ac
© 2016 The Korean Society of Coloproctology
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Annals of
Coloproctology
www.coloproctol.org 151
Volume 32, Number 4, 2016
Ann Coloproctol 2016;32(4):150-155
CASE REPORTS
Case 1
A 58-year-old man presented with lower rectal swelling, bleeding, 
and anemia for 3 years. He was a diabetic patient with no family 
history of colorectal cancer. A colonoscopy revealed a rectal mass 
4 cm above the anal verge (AV), and histopathology from another 
hospital showed a poorly differentiated carcinoma. His serum 
carcinoembryonic antigen (CEA) level was 4.06 ng/mL. Pelvic 
magnetic resonance imaging (MRI) and computed tomography 
(CT) of the abdomen and the pelvis showed a fungating mass in 
the lower rectum extending to the anal canal, with multiple lymph 
nodes (LNs) in the perirectal and right pelvic side wall without 
any other evidence of distant metastasis (Fig. 1A). Whole-body 
positron emission tomography-CT showed intense fluorodeoxy-
glucose uptake in the LNs at the perirectal and both iliac chains 
without any suggestion of distant metastasis. 
To differentiate the type of cancer, the patient underwent re-bi-
opsy. This revealed a poorly differentiated carcinoma, suggestive 
of a squamous-cell type. Therefore, additional immunohisto-
chemical staining and a special stain analysis were performed. 
From the stains, p40 was positive and CK20, CEA, and HMB45 
were negative in the tumor cells. Based on the diagnosis of a SCC, 
the patient started concurrent chemo-radiotherapy (CCRT) for 6 
weeks, based on a regimen of fluorouracil and mitomycin C with 
50.4 Gy. One month after CCRT, follow-up rectal MRI and ab-
dominal and pelvic CT were performed. The scans showed a re-
duction in the size of the pedunculated mass protruding into the 
anal canal with no extramural extension. Also noted was a reduc-
tion in the sizes of the perirectal and the right iliac LNs (Fig. 1B). 
However, the patient still presented with a prolapsing anal mass 
(Fig. 1C). 
After a multidisciplinary team approach, the patient underwent 
excision of the prolapsed lesion to confirm the pathology, which 
showed no residual tumor with nonspecific inflammation. Two 
months later, rectal MRI showed a new 8.4 × 3.1-cm lobulating 
mass that involved the entire anal canal and low rectum and was 
suspected to be a recurrent tumor. A rebiopsy was performed, 
and the pathology report showed a poorly differentiated carci-
noma expressing p63 and p40, consistent with a SCC, while 
CDX2 and HMB45 were negative in the tumor cells (Table 1). 
The patient had an abdominoperineal resection, and the pathol-
ogy report showed Mandard grade IV regression with a poorly 
differentiated carcinoma and squamous differentiation, classified 
as ypT3N0M0. All of the margins were free, but lymphovascular 
invasion (LVI) and perineural invasion were seen. The permanent 
immunohistochemical staining results showed positive p40 with 
weakly positive p63, and negative CDX2 staining (Fig. 2). The pa-
Table 1. Results of stains for cases 1 and 2
Case Stain Result
1 p40 +
p63 +
CK20 −
CEA −
CDX2 −
HMB45 −
2 p40 +
p63 +
CEA +
CK20 +
CDX2 −
D-PAS +
Fig. 1. (A) Pelvic magnetic resonance imaging (MRI) revealed a 6.1-cm fungating mass involving the lower rectum (4 cm from the anal verge). 
Multiple regional lymph node metastases were suspected. (B) Post concurrent chemo-radiotherapy MRI shows a decrease in the size of the pe-
dunculated mass protruding into the anal canal (from 6 cm to 4.7 cm in size) with no extramural extension. (C) Encircled prolapsed anal mass.
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tient was administered 5-fluorouracil and cisplatin chemotherapy 
after surgery, and he is now on his third chemotherapy cycle.
Case 2
A 73-year-old woman presented with a 3-month history of 
changes in stool habit and stool caliber. She had a positive stool 
occult blood test, and her serum CEA level was 1.69 ng/mL. 
Colonoscopy showed 2 masses; one was 1 cm from the AV, and 
the other was 8.5 cm from the AV (Fig. 3A). The pathology report 
from another hospital indicated a diagnosis of a poorly differenti-
ated carcinoma. Rectal MRI and CT of the abdomen and the pel-
vis showed a fungating mass in the midrectum, with perirectal fat 
infiltration and multiple enlarged LNs in the mesorectum. No 
pelvic side wall or para-aortic lymphadenopathy was indicated 
(Fig. 3B), and chest CT showed no evidence of intrathoracic me-
tastasis. Rebiopsy was performed for suspected lesions, and the 
pathology report showed a fragment of scattered tumor cells with 
p63-positive nuclei, consistent with a SCC. 
Because the disease was considered as T1 anal cancer and T3 
rectal cancer positive for a circumferential resection margin 
(CRM), a multidisciplinary team decided to start neoadjuvant 
CCRT. After 4 weeks of Xeloda-based 50.4-Gy CCRT, follow-up 
rectal MRI and CT of the abdomen and the pelvis showed de-
creased tumor volume with mesorectal infiltration, but the scans 
were still positive for CRM at the 8 o’clock position with no sig-
nificant LNs in the pelvic cavity or evidence of distant metastasis 
(Fig. 3C). Ten weeks after CCRT, the patient underwent a laparo-
scopic-assisted low anterior resection with double stapling for 
rectal cancer and a transanal excision for anal cancer (Fig. 4). The 
pathological diagnosis after surgery showed post-CCRT status 
with fibrosis outgrowing the residual cancer with a main diagno-
sis of a poorly differentiated adenosquamous carcinoma. LVI was 
positive, and an ulcerative 2.5 × 1.5-cm mass with a classification 
of ypT3N0M0 was seen. 
Fig. 2. (A) Positive in tumor cells showing squamous differentiation (P40, ×200), (B) weakly positive in tumor cells showing squamous differen-
tiation (P63, ×200), (C) negative in tumor cells showing squamous differentiation (CDX2, ×200). 
Fig. 3. (A) Colonoscopy showed two masses, the first being 1 cm and 
the second 8.5 cm from the anal verge. (B) Rectal magnetic resonance 
imaging (MRI) showing a fungating mass in the mid rectum 8.5 cm 
from the anal verge with perirectal fat infiltration and multiple en-
larged lymph nodes in the mesorectum. (C) Rectal MRI after concur-
rent chemo-radiotherapy showed a decrease in the tumor size with 
still a positive circumferential resection margin at 8 o’clock direction.
A
A
C
C
B
B
Annals of
Coloproctology
www.coloproctol.org 153
Volume 32, Number 4, 2016
Ann Coloproctol 2016;32(4):150-155
The immunohistochemical stain results showed positive for p40 
and p63, suggesting a squamous cell carcinomatous component. 
Additionally, CEA and CK20 were positive for the adenocarcino-
matous component, and CDX2 was negative in the tumor cells. 
D-PAS stain revealed focal mucin deposits in the tumor cells (Ta-
ble 1). A follow-up CT scan of the abdomen and the pelvis one 
month after the surgery showed no evidence of tumor recurrence 
or metastasis, and the patient started on 4 cycles of FP (5-fluoro-
Table 2. Immunohistochemical stain markers used to distinguish between the adenomatous and squamous components
Marker Stain General Uses
p40 deltaNp63 p63 isoforms Classify nonsmall cell lung carcinoma:
-Adenocarcinoma (deltaNp63 −ve or <2% of cells with weak staining)
-Squamous cell carcinoma (deltaNp63+ve [strong] and >50% of cells)
-Adenosquamous (deltaNp63+ve [strong] and < 50% of cells) [15, 16] 
CK20 Cytokeratin20 Epithelial marker with restricted 
expression compared with 
CK7
-CK7−/CK20+: carcinoma of the colon, particularly early stage [17]
-CK20 is less sensitive for poorly differentiated colonic carcinomas [18]
-Primary mucinous tumors of lower gastrointestinal tract [19]
-To help distinguish colon carcinomas (80% are CK20+) at biopsy [20]
- To distinguish anal carcinomas (CK7+/CK20−) from downward growth of colorectal  
carcinomas [21]
CEA CD66e Colorectal carcinoma:
-Monitor serum levels (elevated in 72%–97%) to detect recurrence [22]
-Elevated preoperative serum levels are a poor prognostic factor [23]
- Elevated levels also present in cirrhosis, biliary obstruction, hepatitis, inflammatory 
bowel disease, smokers and post-surgical bowel sequestration with mucocele [24]
HMB45 Human melanoma black 45 Pmel 17 - Reacts against an antigen present in melanocyte tumors; 92% sensitivity when used to 
identify melanomas [25]
p63 Tap63, deltaNp63 Member of p53 gene family - Determines squamous differentiation (p63+) for hematoxylin-eosin or cytology cases as 
part of a panel [26], but p63 rarely stains an adenocarcinoma [27]
CDX2 Homeobox gene that encodes a 
nuclear transcription factor 
critical for intestinal embry-
onic development
- Fairly specific marker of gastrointestinal origin for adenocarcinomas, but also stains  
selected adenocarcinomas of other sites [28]
-Used to determine the origin of a metastatic adenocarcinoma as part of the panel [29]
-Distinguish primary and secondary colorectal adenocarcinomas [30]
Fig. 4. (A) H&E, ×100, (B) positive in squamous cell carcinomatous component (P40, ×100), (C) positive in squamous cell carcinomatous com-
ponent (P63, ×40), (D) positive in adenocarcinomatous component (CEA, ×40), (E) positive in adenocarcinomatous component (CK20, ×100), 
(F) negative in tumor cells (CDX2, ×40), and (G) focal mucin deposits in tumor cells (D-PAS, ×100).
A
E
B
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uracil and cisplatin) chemotherapy. The FP chemotherapy has 
been completed, and the patient is being followed up at an outpa-
tient clinic without any recurrence.
DISCUSSION
Colorectal cancer is a common disease that usually presents with 
an adenocarcinoma histology. However, only a few reports in the 
literature are concerned with colorectal SCCs. The etiology of a 
SCC is uncertain. According to Balfour, a true SCC of the colon 
and rectum does not exist, and this disease might represent me-
tastasis from other sites or squamous degeneration of a pre-exist-
ing adenocarcinoma. However, this opinion is not widely ac-
cepted [6]. Several other theories have attempted to explain the 
histopathogenesis of these tumors. These theories include (1) the 
presence of embryologic nests of ectodermal cells in the colonic 
mucosa; (2) the occurrence of squamous metaplasia of the intesti-
nal mucosa, specifically in colonic adenomas; (3) the capability of 
pluripotent stem cells of endodermal origin to transform into an 
adenocarcinoma, a SCC, or both; and (4) possible cellular degen-
eration within an existing adenocarcinoma secondary to an ab-
normal mucosa stimulus such as ulcerative colitis or radiation  [1, 
7]. Because defining an adenocarcinoma, an adenosquamous car-
cinoma or a SCC, is difficult in poorly differentiated cancer, sev-
eral immunohistochemical markers are used to distinguish squa-
mous-cell disease from an adenocarcinoma (Table 2). 
Hematoxylin-eosin (H&E) staining is first applied to detect 
whether the adenomatous morphology is present. Following the 
stain analysis, if clarifying the type is still difficult, extra immuno-
histochemical stains should be used. In this report, both cases re-
quired extra staining to confirm the diagnosis because the pri-
mary result was only a poorly differentiated carcinoma. p40 and 
p63 are important markers for discriminating squamous cell 
components from adenocarcinoma components because these 
markers are positive in SCCs. p63 is p53 homolog nonspecific an-
tibody, subdivided by TAp63 and deltaNp63, which is called p40, 
so the expression of deltaNp63, as well as that of p63, is compared 
with both the clinical and the pathological factors and prognosis 
[8]. 
In the first case, we also stained with HMB45 to distinguish this 
cancer, which presented very poor differentiation in the anus, 
from a malignant melanoma. Furthermore, because H&E stain-
ing suggested an adenosquamous carcinoma in the second case 
study, D-PAS, which can be derived from an adenocarcinoma, 
was stained only in the second case. In both cases, additional 
staining for the expressions of CEA, CK20, and CDX2 was per-
formed. These markers are positive in an adenocarcinoma, possi-
bly aiding in the discrimination of the adenomatous component 
from the primary cancer. 
Early discrimination of a rectal adenocarcinoma from an adeno-
squamous carcinoma or a SCC is critical because of differences 
among prognoses. For instance, the prognosis for a rectal SCC is 
worse than that of other parts of the colon [9]. A preoperative di-
agnosis is difficult because the clinical presentation of a SCC is 
similar to that of an adenocarcinoma; symptoms include abdomi-
nal pain, anemia, weight loss, rectal bleeding, and tenesmus [10, 
11]. Thus, with the help of immunohistochemical staining analy-
sis, discriminating among a rectal adenocarcinoma, adenosqua-
mous disease, and a SCC is possible. The squamous epithelial 
components have more invasive tendencies than the glandular 
components [7], and the survival rates are lower in the epithelial 
components [10, 11]. Furthermore, in cases of LN metastasis, the 
prognosis for an adenosquamous carcinoma or a SCC is much 
worse than that for an adenocarcinoma alone [6]. The 5-year sur-
vival rate for a node-positive adenosquamous carcinoma or a 
SCC is 23% compared with 85% for node-negative cases. The 
overall 5-year survival rate for an adenosquamous carcinoma or a 
SCC is 31% compared with 66% for an adenocarcinoma [12]. 
Overall, surgical resection is traditionally considered the most 
effective treatment not only to cure the patient but also to confirm 
the pathology. Some researchers have suggested that chemoradia-
tion may be an effective treatment, or even consider it a definitive 
treatment, reserving surgery for patients for whom chemoradia-
tion treatment has failed [10, 13]. The low acute toxicity of 
chemoradiation and the rare incidence of long-term toxicity, re-
ported as symptomatic rectal stricture, are reasons to consider 
treatments other than surgery, which has the risks of morbidity 
and mortality [14]. Thus, chemotherapy or radiotherapy should 
be considered, especially in node-positive cases, although further 
investigation is needed regarding whether to treat patients with 
chemotherapy or radiotherapy alone or to treat them with a com-
bination of these therapies. 
In summary, compared to an adenocarcinoma, an adenosqua-
mous carcinoma and a SCC exhibit both poor prognoses and dif-
ficulties in determining treatment plans. Using several immuno-
histochemical stains, we were able to distinguish squamous com-
ponents from adenomatous components, especially in patients 
with poorly differentiated cancer. By differentiating between an 
adenosquamous carcinoma and a SCC, physicians may employ 
more effective treatments for these rare malignancies. 
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